The phase 2 BEACON trial evaluated brepocitinib, an oral tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, in 31 adults with biopsy-proven active cutaneous sarcoidosis. Participants received once-daily brepocitinib 45 mg, 15 mg, or placebo for 16 weeks. At week 16, Cutaneous Sarcoidosis Activity and Morphology Instrument–Activity (CSAMI-A) scores improved by 22.3 and 22.2 points with the respective brepocitinib doses, compared with 0.7 points with placebo (P<.001).With 45 mg brepocitinib, 69.2% achieved clear or almost clear skin, 76.9% achieved at least 50% CSAMI-A improvement, and 61.5% achieved a CSAMI-A score below 5. Improvements were evident by week 4 and extended to difficult-to-treat presentations, including lupus pernio.

Skin-related quality of life also improved. No deaths or serious adverse events occurred. Brepocitinib demonstrated rapid and clinically meaningful…